We are developing an entirely novel class of orally available small molecules to address untreatable cancers.
Our first drug, Ag5, aims to redefine the treatment landscape for solid tumours on both sides of the blood brain barrier by targeting the 30% of all cancers that generate high levels of Reactive Oxygen Species. This large group contains cancers driven by mutations in the KRAS gene, triple negative breast cancer and glioblastoma-all of which are urgent unmet medical needs with large potential markets.
We have a deep pipeline of follow on medicines. Our goal is to revolutionise cancer treatment for patients and their doctors.
Company Details
- Employees
- 10
- Founded
- -
- Address
- Polig. Ind. Novo Milladoiro C/ Xesta, Nº 78a., Milladoiro,a Coruña,15895,spain
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- HQ
- Milladoiro, A Coruña
Arjuna Therapeutics Questions
Arjuna Therapeutics's LinkedIn profile is https://www.linkedin.com/company/arjunatherapeutics
Arjuna Therapeutics has
10 employees.
View email and phone details for 10
employees at Arjuna Therapeutics.
Arjuna Therapeutics's industry is
Pharmaceutical Manufacturing
Arjuna Therapeutics's top competitors are
Capital Cell,
Amadix,
Gat Biosciences S.l,
Nema-Health,
Zecardio Therapeutics,
Brilliant Group, Inc.,
Abilitypharma,
Ahead Therapeutics,
Nanogap,
Nostrum Biodiscovery.
Arjuna Therapeutics's categories are Pharmaceutical Manufacturing
Arjuna Therapeutics's founding year is 2019
